Gannet BioChem and Serina Therapeutics have entered a development partnership under which Gannet will support development activities for SER-252, Serina’s investigational therapy for advanced Parkinson’s disease. SER-252 recently received clearance of its investigational new drug application from the U.S. Food and Drug Administration, enabling the program to advance into clinical development. The collaboration pairs Serina’s […] The post Serina Therapeutics, Gannet BioChem partner to develop advanced Parkinson’s treatment appeared first on Longevity.Technology.

לצפייה בכתבה המקורית והרחבה: https://longevity.technology/news/serina-therapeutics-gannet-biochem-partner-to-develop-advanced-parkinsons-treatment/